CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies

Inclusion Criteria: 1. Diagnosed CD7 positive relapsed/refractory hematological malignancies. 2. Echocardiography shows left ventricular ejection fraction (LVEF) ≥ 50%; 3. There is no active pulmonary infection, and the oxygen saturation during air inhalation is more than 92%; 4. The estimated survival time is more than 3 months; 5. Eastern cooperative oncology group (ECOG) performance status of 0 to 2 6. The patients or their legal guardians voluntarily participated in the trial and signed the informed consent. Exclusion Criteria: 1. Patients with history of epilepsy or other central nervous system diseases; 2. Patients with prolonged QT or severe heart disease; 3. Pregnant or lactating women 4. Patients with uncontrolled active infection. 5. Positive for any of the following etiological tests: HIV, HBV, HCV 6. Any other conditions that researcher think it is inappropriate for the subject to anticipate the trial